Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation.

[1]  T. Sasaki,et al.  Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil. , 1997, Transplantation.

[2]  F. Martinez,et al.  Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. , 1997, The Annals of thoracic surgery.

[3]  R. Speich,et al.  Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: importance of dosage. , 1997, Transplantation.

[4]  R. Novick,et al.  The Registry of the International Society for Heart and Lung Transplantation: fourteenth official report--1997. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  W. Klepetko,et al.  Influence of human leukocyte antigen matching on long-term outcome after lung transplantation. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  G. Remuzzi,et al.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1996, Transplantation.

[7]  S. Yousem,et al.  Significance of clinically silent untreated mild acute cellular rejection in lung allograft recipients. , 1996, Human pathology.

[8]  L. Sharples,et al.  Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation--early risk factors. , 1996, Transplantation.

[9]  G. Berry,et al.  Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  G. Berry,et al.  Obliterative bronchiolitis after lung and heart-lung transplantation. , 1995, The Annals of thoracic surgery.

[11]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[12]  B. Griffith,et al.  Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. , 1995, The Journal of thoracic and cardiovascular surgery.

[13]  P Fauchald,et al.  PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .

[14]  D. Renlund,et al.  Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15]  B. Griffith,et al.  A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. , 1994, American journal of respiratory and critical care medicine.

[16]  B. Griffith,et al.  Airway obstruction and bronchiolitis obliterans after lung transplantation. , 1993, Clinics in chest medicine.

[17]  D. Kapelanski,et al.  Lung transplantation without the use of antilymphocyte antibody preparations. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  B. Griffith,et al.  A decade of lung transplantation. , 1993, Annals of surgery.

[19]  N. G. Best,et al.  Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome , 1993, Clinical pharmacology and therapeutics.

[20]  H. Sollinger,et al.  Prolongation of canine intestinal allograft survival with RS-61443, cyclosporine, and prednisone. , 1993, Transplantation.

[21]  B. Griffith,et al.  Acute rejection of lung allografts with various immunosuppressive protocols. , 1992, The Annals of thoracic surgery.

[22]  M. Pasque,et al.  The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. , 1992, Chest.

[23]  B. Griffith,et al.  Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. , 1992, The Annals of thoracic surgery.

[24]  T. Merigan,et al.  A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. , 1992, The New England journal of medicine.

[25]  W. Bechstein,et al.  RS-61443 reverses acute allograft rejection in dogs. , 1991, Surgery.

[26]  B. Griffith,et al.  Does histologic acute rejection in lung allografts predict the development of bronchiolitis obliterans? , 1991, Transplantation.

[27]  A. Allison,et al.  Lymphocyte‐Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion , 1991, Scandinavian journal of immunology.

[28]  G. Berry,et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.

[29]  M. Hammond,et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.

[30]  A. Allison,et al.  Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. , 1990, Transplantation proceedings.

[31]  K. Lafferty,et al.  RS-61443 allows islet allografting and specific tolerance induction in adult mice. , 1990, Transplantation proceedings.

[32]  B. Griffith,et al.  Immunologically Mediated Disease of the Airways after Pulmonary Transplantation , 1988, Annals of surgery.

[33]  R. Schwartz,et al.  Drug-induced Immunological Tolerance , 1959, Nature.

[34]  B. Griffith,et al.  Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. , 1995, The Journal of thoracic and cardiovascular surgery.

[35]  G. Patterson,et al.  A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[36]  G. Klintmalm,et al.  RS-61443 for treatment-resistant human liver rejection. , 1993, Transplantation proceedings.

[37]  D. Eckhoff,et al.  RS-61443--a new, potent immunosuppressive agent. , 1991, Transplantation.

[38]  J. Maurer,et al.  Pulmonary considerations in transplantation. , 1990, Clinics in chest medicine.

[39]  M. Spino.  Pharmacokinetics of drugs in cystic fibrosis. , 1990 .

[40]  S. Yousem.  Heart-lung transplantation. , 1989, Perspectives in pediatric pathology.